Sample Solution
I would not respect the cultural practice and not inform a patient about the prognosis. As healthcare professionals it is our responsibility to provide accurate information to patients so they can make informed decisions about their health; this includes informing them of potential risks associated with any treatment plans or expected outcomes (Ludwick et al., 2020). Therefore by withholding this knowledge from individuals we are essentially denying them the right to choose what course of action to take for themselves which goes against ethical principles of medicine.
There is a way for health care providers to balance the patient’s right to know with respect for the cultural practices and beliefs of the family. A key factor in this situation is engaging in active communication with both parties which will help ensure that everyone’s rights and needs are taken into consideration (Ludwick et al., 2020). This could involve explaining various treatment options while also honoring any particular cultural practices that may exist; if issues arise then healthcare professionals should be willing to discuss them openly in order to reach an agreement on the best course of action.
Additionally, it may be beneficial to engage other members of community such as religious leaders or family elders who can provide additional guidance when needed. Ultimately then, by involving all stakeholders together we can work towards finding mutually acceptable solution that respects wishes of both patients & families alike without compromising individual rights.
No, it would not be appropriate to respect this cultural practice and not inform a patient about their prognosis. Informing patients of their diagnosis and treatment options is an integral part of informed consent in medical care. It is unethical for healthcare providers to withhold information from patients that could affect their decisions or choices related to care.
It is possible for health care providers to work with families to ensure that the patient’s rights are respected while also respecting the cultural practices and beliefs of the family. This may include providing both the patient and family with accurate information about prognosis, treatments, and potential outcomes as well as involving family members in decision-making processes
The basic aim of the personalized medicine is applying right therapy to the right population of people by defining disease at the moecular level. So, identifying differences among the individuals support the new treatment methods and pharmaceutical companies to develop new cancer drugs. Patients who have similar clinical outcome and histological tumor type can give different response to the same drug(17). Prediction of who will be a nonresponders reduces the harmfull effect of drug on nonresponders like a potential toxic effect of drug and cost effect. Also when drug companies develop new drug, they focus on the patient population that benefit from drug to increase positive responds(17).
U.S. Food and Drug Administration bringed development about targeted therapy. For example, to treat chronic myeloid leukemia and gastrointestinal stromal tumor(18) ,imatinib mesylate is used and to treat breast cancer(19), trastuzumab (Herceptin) is used. Molecular characteristics of these cancer types that are abnormal protein tyrosine kinase activity in chronic myeloid leukemia and gastrointestinal stromal tumor and HER-2 receptor in breastcancer is used as a predictive biomarker. By using these markers only individuals which have these molecular alteration is selected and it means they are favorable for the treatment. Using this way some cancer types’ survival rate is shifted from 0 to 70%(17).
This application is used in non-small cell lung cancer treatment with using of mutations screeing. In this cancer type mutation occurs in kinase domain of EGFR. Gefitinib (Iressa) and erlotinib are tyrosine kinase inhibitors drug are used to treat and patients give a higher response to the treatment(20). Also if patient that is never smoked Asian females have adenocarcinomas, these drugs efficient on them(21). On the other hand, if the mutatuions occur at downstream effector KRAS, patient is resistant to to erlotinib(22). Also mutations that is at KRAS have a resistance to cetuximab (Erbitux) and panitumumab (Vectibix) drugs in colon cancer patients. If the KRAS is wild type, these these drugs is effective on the patients(23). These responses that are specific and different are based on molecular profile. Some molecular test are done before the using of cetuximab or panitumumab to a colon cancer patient. Lung and colon cancer is concerned with targeted therapy that is guide to patient about treatment by understanding the structure of cancer(24).
Pharmacogenomics and treatment safety
Genes that have genetical variation encode enzymes which metobolize drug, drug transporters, or drug targets. Variation in genes that can predict dose and safety of treatment for different types of cancer patient can have harmful influence on these patients’ treatment(25). For instance, polymorphism where in cytochrome P450 enzymes could cause to metabolite to drug slowly or very fast. So patient give an overdose symptoms or no response to drug by changing the pharmacokinetics of drug metabolism, also it may cause an adverse drug reaction(26). Thereby , forecasting optimal dose of drug , inducing the harmful side effects can be provided by using polymorphism(27). In familial breast cancer, patients shows low survival rate to treatment with tamoxifen that is chemotherapeutic drug because of genetic variation in CYP2D6 that is seen as a poor metabolizer (28). There are some studies abour genetic testing on drug label including test for CYP450 polymorphisms.
Prognosis
Insteaf of using clinicopathologic parameters as a biomarker in biochemical testing for prognosis and selection of therapatic way for cancer patient , Genotyping or gene expression profiling by microarray and protein analysis by mass spectrometry is used for prognostic biomarkers with the understanding of the molecular mechanism of cancer subtypes(29).
Biomarkers can be used alone or with combination of other parameters for classify subgroups according to their risk rate and for leading to therapy decision. For example, tissue microarray analysis with combining molecular and clinical biomarker is more efficient than the clasical cl
Hi, Welcome to Compliant Papers.